Drug ID:Drug151
Drug Name:Uproleselan
CID:71600085
DrugBank ID:DB14829
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NULL
Molecular Formula:C60H109N3O27
Molecular Weight:1304.5 g/mol
Isomeric SMILES:CC[C@H]1C[C@H](C[C@H]([C@@H]1O[C@H]2[C@H]([C@@H]([C@@H]([C@@H](O2)C)O)O)O)O[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O[C@@H](CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
Synonyms:Uproleselan; GMI-1271; 1983970-12-2; Uproleselan [USAN]; GMI-1271 FREE ACID; PE952ANF83; (S)-2-(((2R,3R,4R,5R,6R)-3-Acetamido-2-(((1R,2R,3S,5R)-3-ethyl-5-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carbamoyl)-2-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)cyclohexyl)oxy)-5-hydroxy; UPROLESELAN [INN]; Uproleselan (USAN/INN); UNII-PE952ANF83
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1186 71600085 Uproleselan 6401 SELE Homo sapiens (human) 33477563 Antagonist
dt1187 71600085 Uproleselan 3200 HOXA3 Homo sapiens (human) Inhibitor
dt1188 71600085 Uproleselan 6401 SELE Homo sapiens (human) 33477563 Selectin E antagonist
dt1189 71600085 Uproleselan 6401 SELE Homo sapiens (human) Inhibitor
dt1190 71600085 Uproleselan 6401 SELE Homo sapiens (human) None
dt1191 71600085 Uproleselan 6401 SELE Homo sapiens (human) 37713619 Inhibitor

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03863886 Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis NA UNKNOWN Carilion Clinic Crohn Disease|Ulcerative Colitis PROCEDURE: Endoscopic ultrasound catheter (UM-2R/… Details
NCT02293811 Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa NULL TERMINATED Centre Hospitalier Universitaire de Nice Crohn Disease-Associated Colorectal Adenocarcinoma OTHER: Analysis Details
NCT05707429 Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) NULL COMPLETED Assiut University Sexual Function Disturbances|Inflammatory Bowel D… OTHER: The Arabic version of The International In… Details
NCT05701501 Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD NA UNKNOWN Changhai Hospital Inflammatory Bowel Diseases DRUG: Vitamin B5 Tablets|DRUG: placebo Details
NCT05688852 VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease PHASE2 TERMINATED Ventyx Biosciences, Inc Crohn Disease DRUG: VTX958|DRUG: VTX958|DRUG: VTX958 Placebo Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05684484 Role of Roflumilast in Ulcerative Colitis PHASE4 COMPLETED Tanta University Ulcerative Colitis DRUG: Roflumilast 500 MCG Oral Tablet [DALIRESP]|… Details
NCT05668013 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Teva Branded Pharmaceutical Products R&D LLC Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… Details
NCT05666960 R-3750 in Patients With Mild to Moderate Ulcerative Colitis PHASE1 RECRUITING Rise Therapeutics LLC Ulcerative Colitis Chronic Mild|Ulcerative Coliti… DRUG: R-3750 Details
NCT05663671 Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD NULL UNKNOWN Meharry Medical College Inflammatory Bowel Diseases|Ulcerative Colitis|Cr… DIAGNOSTIC_TEST: Diagnostic Test Details
NCT05659953 LMT503 First-in-human SAD, MAD, and FE Study PHASE1 NOT_YET_RECRUITING Lmito Therapeutics Inc. Inflammatory Bowel Disease|Colitis, Ulcerative|Cr… DRUG: LMT503|DRUG: Placebo Details
NCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years PHASE3 RECRUITING Ardelyx Irritable Bowel Syndrome With Constipation (IBS-C) DRUG: Tenapanor 50 MG|DRUG: Tenapanor 25 mg bid|D… Details
NCT05638347 A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. PHASE1 COMPLETED Atridia Pty Ltd. Inflammatory Bowel Disease DRUG: HRS-7085 tablets|DRUG: Placebo tablet Details
NCT05624801 Cholecalciferol Comedication in Patients With Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C-study PHASE3 Recruiting University Hospital, Basel, Switzerland IBD Drug: D3 VitaCaps Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC PHASE2 ACTIVE_NOT_RECRUITING Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Inflammatory Bowel Diseases|Colitis, Ulcerative DRUG: MORF-057|DRUG: Placebo Details
NCT05549323 A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis PHASE1 TERMINATED Pfizer Ulcerative Colitis DRUG: PF-07054894|DRUG: Placebo Details
NCT07161297 Remimazolam for Colonoscopy in IBD Patients PHASE4 NOT_YET_RECRUITING Humanitas Clinical and Research Center IBD (Inflammatory Bowel Disease) DRUG: Intravenous remimazolam (5 mg initially, wi… Details
NCT05499130 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 COMPLETED Teva Branded Pharmaceutical Products R&D, Inc. Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574|DRUG: Placebo Details
NCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Ganzhou Hemay Pharmaceutical Co., Ltd Moderate to Severe Ulcerative Colitis DRUG: Hemay005 tablets|DRUG: Hemay005 placebo tab… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations